CSL inks $313m deal to bring ‘next-generation’ flu, COVID vaccines to Australia
Biotech giant CSL will accelerate investment in messenger-RNA technologies through a $313 million licensing deal with US medicines maker Arcturus Therapeutics, which is developing mRNA…